Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer ...

The total potential value of the agreement, including development, regulatory, and commercial milestones, could reach $11.1 ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

The deal will see BMS pay BioNTech $1.5bn in an upfront payment and $2bn total in "non-contingent anniversary payments" ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

Biopharmaceutical stocks are in focus on Monday after Bristol-Myers Squibb (BMY) announced an $11 billion partnership with ...

It was a mixed day for healthcare stocks, as gains for UnitedHealth and Eli Lilly counterbalanced losses for Centene and Thermo Fisher. BioNTech leapt higher following news of a new deal with Bristol ...

Bristol-Myers announces $11 billion cancer partnership with BioNTech. CEO Boerner dubs the team up the next new frontier in ...

BioNTech (NASDAQ:BNTX) surged 20% after Bristol Myers Squibb agreed to license its bispecific antibody BNT327targeting PD-L1 ...

Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing ...